Form 8-K - Current report:
SEC Accession No. 0001494650-25-000062
Filing Date
2025-03-26
Accepted
2025-03-26 07:04:50
Documents
16
Period of Report
2025-03-26
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K optn-20250326.htm   iXBRL 8-K 27764
2 EX-99.1 a20241231earningspr1.htm EX-99.1 68238
6 image_0.jpg GRAPHIC 10067
7 optn-20250326_g1.jpg GRAPHIC 10067
  Complete submission text file 0001494650-25-000062.txt   268663

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT optn-20250326.xsd EX-101.SCH 1785
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT optn-20250326_lab.xml EX-101.LAB 21689
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT optn-20250326_pre.xml EX-101.PRE 12525
18 EXTRACTED XBRL INSTANCE DOCUMENT optn-20250326_htm.xml XML 2722
Mailing Address 777 TOWNSHIP LINE ROAD SUITE 300 YARDLEY PA 19067
Business Address 777 TOWNSHIP LINE ROAD SUITE 300 YARDLEY PA 19067 267-364-3500
OptiNose, Inc. (Filer) CIK: 0001494650 (see all company filings)

EIN.: 421771610 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38241 | Film No.: 25770104
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)